GYRE Gyre Therapeutics Inc.
Company Analysis
Latest News
Gyre Therapeutics Downgraded to Strong Sell, Following Earnings Miss
Zacks Research downgraded Gyre Therapeutics from hold to strong sell on August 20, 2026. This revision signals a bearish outlook for the company’s near-term...
🔴 Gyre Therapeutics falls 5.0% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
Gyre Therapeutics faces liquidity risks, citing concentrated ownership and loan exposure
An analyst warned today of significant risks for Gyre Therapeutics stock due to thin trading volume. Insiders and GNI Parties maintain a heavy ownership...
Gyre Therapeutics Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 10, 2026
For the second quarter of 2026, analysts expect Gyre Therapeutics to report consensus revenue of $26.49 million and an EPS loss of $0.08, while the stock...
Gyre Therapeutics second quarter 2026 revenue reached $29.1M as China NDA acceptance for F351 progressed
Gyre Therapeutics reported second quarter 2026 revenue of $29.1 million, a 2% year-over-year decrease as growth in core pirfenidone sales was offset by the...
🟢 Gyre Therapeutics is trading 5.17% up today amid broader risk-on market sentiment
Gyre Therapeutics is trading at $6.05 (+5.17%) as of the current session, moving higher despite a lack of company-specific announcements or analyst actions. •...
🔴 Gyre Therapeutics is trading 5.8% down today despite a strong biotech sector
Gyre Therapeutics is trading at $6.05 (5.8% down) today, underperforming a generally strong biotech tape in a move that appears to be stock-specific. • No new...
🔴 Gyre Therapeutics is trading 5.3% down today with no clear catalyst
Gyre Therapeutics is trading 5.3% down at $6.50 today with no fresh, company-specific news hitting the tape to explain the downward move. • Shares appear to...
🟢 GYRE makes sharp 10.9% jump
GYRE is trading at $7.23, up 10.9% versus the comparison close of $6.52 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 GYRE is trading 5.6% up today after filing a resale shelf registration for 30.22 million shares
GYRE is trading 5.6% up at $6.47 amid active trading as investors digest a new shelf registration filing for the potential resale of common stock. • Gyre...
🟢 Gyre Therapeutics Inc. is trading 5.2% up today after stockholders approve preferred stock conversion
Gyre Therapeutics Inc. is trading 5.2% up at $6.12 following stockholder approval for the conversion of Series B Convertible Preferred Stock into common...
GYRE Stockholders Approve Conversion of Series B Preferred Stock at Annual Meeting
Gyre Therapeutics announced that stockholders approved all proposals at its 2026 Annual Meeting of Stockholders held on June 10, 2026. A key approval was the...